StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.14−0.10 (-4.46%)

Close on Nov 17, 2026Market cap $4.83MP/E –Yield –

Biodexa Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -£8.65M. The highest annual figure on record is -£7.00M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-£8.65M–
FY2024Dec 31, 2024-£9.20M–
FY2023Dec 31, 2023-£8.01M–
FY2022Dec 31, 2022-£8.93M–
FY2021Dec 31, 2021-£7.00M–
FY2020Dec 31, 2020-£23.04M–
FY2019Dec 31, 2019-£11.32M–
FY2018Dec 31, 2018-£11.82M–
FY2017Dec 31, 2017-£13.28M–
FY2016Dec 31, 2016-£9.65M–
FY2015Dec 31, 2015-£12.92M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?